Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,575.00 DKK | +0.77% | +0.38% | +5.53% |
01-02 | A poor 2024 increases the odds of a brighter 2025 | |
12-20 | Bernstein Upgrades Genmab to Market Perform, Lowers PT | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 5.37B | 10.11B | 8.48B | 14.6B | 16.47B | |||||
Total Revenues | 5.37B | 10.11B | 8.48B | 14.6B | 16.47B | |||||
Cost of Goods Sold, Total | - | - | - | - | 226M | |||||
Gross Profit | 5.37B | 10.11B | 8.48B | 14.6B | 16.25B | |||||
Selling General & Admin Expenses, Total | 342M | 661M | 1.28B | 2.68B | 3.3B | |||||
R&D Expenses | 2.39B | 3.12B | 4.18B | 5.52B | 7.63B | |||||
Other Operating Expenses, Total | 2.73B | 3.78B | 5.46B | 8.2B | 10.93B | |||||
Operating Income | 2.64B | 6.34B | 3.02B | 6.4B | 5.32B | |||||
Interest Expense, Total | -7M | -10M | -13M | -21M | -27M | |||||
Interest And Investment Income | 120M | 184M | 197M | 324M | 939M | |||||
Net Interest Expenses | 113M | 174M | 184M | 303M | 912M | |||||
Currency Exchange Gains (Loss) | 99M | -1.46B | 1.47B | 1.03B | -889M | |||||
Other Non Operating Income (Expenses) | - | - | - | - | - | |||||
EBT, Excl. Unusual Items | 2.85B | 5.05B | 4.67B | 7.73B | 5.34B | |||||
Gain (Loss) On Sale Of Investments | 9M | 873M | -689M | -659M | 293M | |||||
Asset Writedown | - | -22M | - | -38M | - | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | 2.86B | 5.9B | 3.98B | 7.04B | 5.64B | |||||
Income Tax Expense | 693M | 1.15B | 975M | 1.51B | 1.28B | |||||
Earnings From Continuing Operations | 2.17B | 4.76B | 3.01B | 5.52B | 4.35B | |||||
Net Income to Company | 2.17B | 4.76B | 3.01B | 5.52B | 4.35B | |||||
Net Income - (IS) | 2.17B | 4.76B | 3.01B | 5.52B | 4.35B | |||||
Net Income to Common Incl Extra Items | 2.17B | 4.76B | 3.01B | 5.52B | 4.35B | |||||
Net Income to Common Excl. Extra Items | 2.17B | 4.76B | 3.01B | 5.52B | 4.35B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 34.4 | 73 | 46 | 84.45 | 66.64 | |||||
Basic EPS - Continuing Operations | 34.4 | 73 | 46 | 84.45 | 66.64 | |||||
Basic Weighted Average Shares Outstanding | 62.96M | 65.18M | 65.4M | 65.39M | 65.31M | |||||
Net EPS - Diluted | 34.03 | 72.21 | 45.54 | 83.65 | 66.02 | |||||
Diluted EPS - Continuing Operations | 34.03 | 72.21 | 45.54 | 83.65 | 66.02 | |||||
Diluted Weighted Average Shares Outstanding | 63.64M | 65.89M | 66.05M | 66.01M | 65.91M | |||||
Normalized Basic EPS | 28.29 | 48.45 | 44.65 | 73.91 | 51.14 | |||||
Normalized Diluted EPS | 27.99 | 47.93 | 44.21 | 73.21 | 50.67 | |||||
American Depositary Receipts Ratio (ADR) | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |||||
Supplemental Items | ||||||||||
EBITDA | 2.78B | 6.56B | 3.27B | 6.72B | 5.56B | |||||
EBITA | 2.74B | 6.44B | 3.1B | 6.46B | 5.38B | |||||
EBIT | 2.64B | 6.34B | 3.02B | 6.4B | 5.32B | |||||
EBITDAR | 2.78B | 6.57B | 3.27B | - | - | |||||
Effective Tax Rate - (Ratio) | 24.24 | 19.41 | 24.48 | 21.51 | 22.8 | |||||
Current Domestic Taxes | 444M | 1.19B | 968M | 1.5B | - | |||||
Total Current Taxes | 444M | 1.19B | 968M | 1.5B | 1.3B | |||||
Deferred Domestic Taxes | 249M | -45M | 7M | 15M | - | |||||
Total Deferred Taxes | 249M | -45M | 7M | 15M | -16M | |||||
Normalized Net Income | 1.78B | 3.16B | 2.92B | 4.83B | 3.34B | |||||
Interest on Long-Term Debt | 7M | 10M | 13M | 21M | 27M | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 342M | 661M | - | - | - | |||||
Research And Development Expense From Footnotes | 2.39B | 3.14B | 4.18B | 5.56B | 7.63B | |||||
Net Rental Expense, Total | 6M | 3M | 1M | - | - | |||||
Imputed Operating Lease Interest Expense | - | 960K | 280K | - | - | |||||
Imputed Operating Lease Depreciation | - | 2.04M | 720K | - | - | |||||
Stock-Based Comp., G&A Exp. (Total) | - | - | - | - | - | |||||
Stock-Based Comp., Other (Total) | 147M | 200M | 310M | 439M | 586M | |||||
Total Stock-Based Compensation | 147M | 200M | 310M | 439M | 586M |